A phase II, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of OTI-010 in subjects who receive HLA [human lymphocyte antigen]-identical sibling peripheral blood stem cell transplantation for hematologic malignancies

Trial Profile

A phase II, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of OTI-010 in subjects who receive HLA [human lymphocyte antigen]-identical sibling peripheral blood stem cell transplantation for hematologic malignancies

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 03 Dec 2014

At a glance

  • Drugs Remestemcel-L (Primary)
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top